Cecilia D Adams, MD | |
6637 Summer Knoll Cir, Suite 101, Bartlett, TN 38134-2875 | |
(901) 372-5260 | |
(901) 386-8726 |
Full Name | Cecilia D Adams |
---|---|
Gender | Female |
Speciality | Family Practice |
Experience | 30 Years |
Location | 6637 Summer Knoll Cir, Bartlett, Tennessee |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1104823020 | NPI | - | NPPES |
3851339 | Medicaid | TN | |
4091779 | Other | TN | BLUE CROSS BLUE SHIELD |
3851336 | Medicaid | TN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 32134 (Tennessee) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Regional One Health | Memphis, TN | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Ut Regional One Physicians Inc | 5698993418 | 270 |
News Archive
Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.
Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
"An analysis of 30,000-year-old bacteria whose DNA has been recovered from the Yukon permafrost shows that they were able to resist antibiotics," providing "the first direct evidence that antibiotic resistance is a widespread natural phenomenon that preceded the modern medical use of antibiotics," according to a study in Thursday's issue of the journal Nature, the New York Times reports.
› Verified 6 days ago
Entity Name | Primehealth Medical Center, Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1104915982 PECOS PAC ID: 7012802465 Enrollment ID: O20040216001090 |
News Archive
Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.
Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
"An analysis of 30,000-year-old bacteria whose DNA has been recovered from the Yukon permafrost shows that they were able to resist antibiotics," providing "the first direct evidence that antibiotic resistance is a widespread natural phenomenon that preceded the modern medical use of antibiotics," according to a study in Thursday's issue of the journal Nature, the New York Times reports.
› Verified 6 days ago
Entity Name | Memphis Urgent Care #2 Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1164840609 PECOS PAC ID: 0648407023 Enrollment ID: O20131210000737 |
News Archive
Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.
Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
"An analysis of 30,000-year-old bacteria whose DNA has been recovered from the Yukon permafrost shows that they were able to resist antibiotics," providing "the first direct evidence that antibiotic resistance is a widespread natural phenomenon that preceded the modern medical use of antibiotics," according to a study in Thursday's issue of the journal Nature, the New York Times reports.
› Verified 6 days ago
Entity Name | Ut Regional One Physicians Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1093130585 PECOS PAC ID: 5698993418 Enrollment ID: O20140820000662 |
News Archive
Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.
Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
"An analysis of 30,000-year-old bacteria whose DNA has been recovered from the Yukon permafrost shows that they were able to resist antibiotics," providing "the first direct evidence that antibiotic resistance is a widespread natural phenomenon that preceded the modern medical use of antibiotics," according to a study in Thursday's issue of the journal Nature, the New York Times reports.
› Verified 6 days ago
Entity Name | Memphis Urgent Care #1, Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1073935003 PECOS PAC ID: 9335468206 Enrollment ID: O20150428001395 |
News Archive
Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.
Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
"An analysis of 30,000-year-old bacteria whose DNA has been recovered from the Yukon permafrost shows that they were able to resist antibiotics," providing "the first direct evidence that antibiotic resistance is a widespread natural phenomenon that preceded the modern medical use of antibiotics," according to a study in Thursday's issue of the journal Nature, the New York Times reports.
› Verified 6 days ago
Entity Name | Carespot Of Memphis, Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1518405034 PECOS PAC ID: 4587940903 Enrollment ID: O20170418002889 |
News Archive
Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.
Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
"An analysis of 30,000-year-old bacteria whose DNA has been recovered from the Yukon permafrost shows that they were able to resist antibiotics," providing "the first direct evidence that antibiotic resistance is a widespread natural phenomenon that preceded the modern medical use of antibiotics," according to a study in Thursday's issue of the journal Nature, the New York Times reports.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Cecilia D Adams, MD 6637 Summer Knoll Cir, Suite 101, Bartlett, TN 38134-2875 Ph: (901) 372-5260 | Cecilia D Adams, MD 6637 Summer Knoll Cir, Suite 101, Bartlett, TN 38134-2875 Ph: (901) 372-5260 |
News Archive
Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.
Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
"An analysis of 30,000-year-old bacteria whose DNA has been recovered from the Yukon permafrost shows that they were able to resist antibiotics," providing "the first direct evidence that antibiotic resistance is a widespread natural phenomenon that preceded the modern medical use of antibiotics," according to a study in Thursday's issue of the journal Nature, the New York Times reports.
› Verified 6 days ago
Michele E Neal, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3091 Kirby Whitten Pkwy, Bartlett, TN 38134 Phone: 901-752-6963 Fax: 901-759-4704 | |
Charolette Jackson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6644 Summer Knoll Cir, Bartlett, TN 38134 Phone: 901-266-4112 Fax: 901-266-4113 | |
Mrs. Gottumukkala Suneela, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2996 Kate Bond Rd, Suite 203, Bartlett, TN 38133 Phone: 901-382-2044 Fax: 901-382-2085 | |
Tri Minh Nguyen, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6570 Stage Rd Ste 245, Bartlett, TN 38134 Phone: 901-746-9888 Fax: 901-746-9854 | |
Dr. Stephen Michael Desouza, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7424 Us Highway 64 Ste 111, Bartlett, TN 38133 Phone: 901-372-3573 | |
Lindsey Marie Van Fossen, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2735 Galaxie St, Bartlett, TN 38134 Phone: 901-356-8590 |